Oscar L. Laskin

7.4k total citations · 3 hit papers
43 papers, 5.7k citations indexed

About

Oscar L. Laskin is a scholar working on Epidemiology, Molecular Biology and Infectious Diseases. According to data from OpenAlex, Oscar L. Laskin has authored 43 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Epidemiology, 11 papers in Molecular Biology and 9 papers in Infectious Diseases. Recurrent topics in Oscar L. Laskin's work include Herpesvirus Infections and Treatments (14 papers), Cytomegalovirus and herpesvirus research (7 papers) and HIV/AIDS drug development and treatment (5 papers). Oscar L. Laskin is often cited by papers focused on Herpesvirus Infections and Treatments (14 papers), Cytomegalovirus and herpesvirus research (7 papers) and HIV/AIDS drug development and treatment (5 papers). Oscar L. Laskin collaborates with scholars based in United States, Switzerland and Canada. Oscar L. Laskin's co-authors include Donna Mildvan, Margaret A. Fischl, Michael H. Grieco, Jerome E. Groopman, Douglas D. Richman, Paul A. Volberding, John M. Leedom, George Gee Jackson, David T. Durack and Michael S. Gottlieb and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Annals of Internal Medicine.

In The Last Decade

Oscar L. Laskin

43 papers receiving 5.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex

1987 2.3k citations Oscar L. Laskin, Donna Mildvan et al. New England Journal of Medicine profile →
The Toxicity of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex

1987 975 citations Oscar L. Laskin, Donna Mildvan et al. New England Journal of Medicine profile →
Acyclovir Prophylaxis of Herpes-Simplex-Virus Infections

1981 425 citations Oscar L. Laskin, Paul S. Lietman et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Oscar L. Laskin United States	25	2.8k	2.3k	2.1k	695	591	43	5.7k
Michael H. Grieco United States	28	3.8k 1.4×	2.6k 1.1×	2.3k 1.1×	589 0.8×	387 0.7×	87	6.7k
John M. Leedom United States	29	3.9k 1.4×	3.0k 1.3×	2.2k 1.1×	575 0.8×	309 0.5×	75	6.3k
Michael S. Gottlieb United States	23	4.1k 1.5×	3.4k 1.5×	3.3k 1.6×	615 0.9×	668 1.1×	41	8.3k
Jan W. Mulder Netherlands	47	3.5k 1.3×	1.2k 0.5×	2.9k 1.4×	614 0.9×	463 0.8×	159	6.3k
Marc Rubin United States	33	2.6k 0.9×	2.2k 1.0×	1.6k 0.7×	1.3k 1.9×	2.1k 3.6×	52	8.1k
Donna Mildvan United States	45	5.3k 1.9×	3.9k 1.7×	3.7k 1.8×	583 0.8×	526 0.9×	130	9.6k
Craig W. Hendrix United States	47	5.7k 2.1×	3.6k 1.6×	3.4k 1.6×	641 0.9×	700 1.2×	259	9.8k
Richard C. Reichman United States	39	4.1k 1.5×	3.2k 1.4×	3.3k 1.6×	679 1.0×	402 0.7×	116	7.4k
Fred Valentine United States	32	3.6k 1.3×	1.5k 0.7×	3.5k 1.7×	571 0.8×	306 0.5×	80	5.8k
Ronald Brookmeyer United States	26	3.2k 1.2×	1.4k 0.6×	4.0k 1.9×	764 1.1×	356 0.6×	43	7.4k

Countries citing papers authored by Oscar L. Laskin

Since Specialization

Citations

This map shows the geographic impact of Oscar L. Laskin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oscar L. Laskin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oscar L. Laskin more than expected).

Fields of papers citing papers by Oscar L. Laskin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Oscar L. Laskin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oscar L. Laskin. The network helps show where Oscar L. Laskin may publish in the future.

Co-authorship network of co-authors of Oscar L. Laskin

This figure shows the co-authorship network connecting the top 25 collaborators of Oscar L. Laskin. A scholar is included among the top collaborators of Oscar L. Laskin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Oscar L. Laskin. Oscar L. Laskin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Laskin, Oscar L., Diksha Kaushik, Jiyuan Ma, et al.. (2023). A pharmacokinetic drug–drug interaction study between rosuvastatin and emvododstat, a potent anti‐SARS‐CoV‐2 (COVID‐19) DHODH (dihydroorotate dehydrogenase) inhibitor. Pharmacology Research & Perspectives. 11(2). e01076–e01076. 2 indexed citations

Ma, Jiyuan, Oscar L. Laskin, Ad F. Roffel, et al.. (2023). Absorption, Metabolism, and Excretion of 14C-Emvododstat Following Repeat Daily Oral Dose Administration in Human Volunteers Using a Combination of Microtracer Radioactivity and High-Radioactivity Doses. Drug Metabolism and Disposition. 52(1). 26–34. 3 indexed citations

Laskin, Oscar L., Diksha Kaushik, Jiyuan Ma, et al.. (2023). A clinical pharmacokinetic drug-drug interaction study between dextromethorphan and emvododstat, a potent anti-SARS-CoV-2 dihydroorotate dehydrogenase inhibitor. European Journal of Clinical Pharmacology. 79(8). 1073–1080. 2 indexed citations

Shapiro, Geoffrey I., Edward O’Mara, Oscar L. Laskin, et al.. (2021). Pharmacokinetics and Safety of PTC596, a Novel Tubulin‐Binding Agent, in Subjects With Advanced Solid Tumors. Clinical Pharmacology in Drug Development. 10(8). 940–949. 14 indexed citations

Infante, Jeffrey R., Philippe L. Bédard, Geoffrey I. Shapiro, et al.. (2017). Phase 1 results of PTC596, a novel small molecule targeting cancer stem cells (CSCs) by reducing levels of BMI1 protein.. Journal of Clinical Oncology. 35(15_suppl). 2574–2574. 13 indexed citations

Hoffmann, Matthew, Gondi Kumar, Peter Schäfer, et al.. (2011). Disposition, metabolism and mass balance of [¹⁴C]apremilast following oral administration. Xenobiotica. 41(12). 1063–1075. 41 indexed citations

Kumar, Gondi, Henry Lau, & Oscar L. Laskin. (2008). Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction. Cancer Chemotherapy and Pharmacology. 63(6). 1171–1175. 28 indexed citations

Christian, Mildred S., et al.. (2007). Evaluation of the developmental toxicity of lenalidomide in rabbits. Birth Defects Research Part B Developmental and Reproductive Toxicology. 80(3). 188–207. 35 indexed citations

Teo, Steve K., Wayne A. Colburn, William Tracewell, et al.. (2004). Clinical Pharmacokinetics of Thalidomide. Clinical Pharmacokinetics. 43(5). 311–327. 108 indexed citations

10.

Schwartz, Jules I., Oscar L. Laskin, Patricia M. Patterson, et al.. (1994). Pharmacodynamics of MK-0963, a new 5α-reductase inhibitor: Effects on serum androgen concentrations. Clinical Pharmacology & Therapeutics. 55(1). 50–54. 1 indexed citations

11.

Laskin, Oscar L., et al.. (1993). Pharmacodynamics and Dose‐Response Relationship of Famotidine: A Double‐Blind Randomized Placebo‐Controlled Trial. The Journal of Clinical Pharmacology. 33(7). 636–639. 7 indexed citations

12.

Saag, Michael S., Emilio A. Emini, Oscar L. Laskin, et al.. (1993). A Short-Term Clinical Evaluation of L-697,661, a Non-Nucleoside Inhibitor of HIV-1 Reverse Transcriptase. New England Journal of Medicine. 329(15). 1065–1072. 125 indexed citations

13.

Depré, Marleen, et al.. (1992). Pharmacodynamics and tolerability of L-654,066, a steroid 5α-reductase inhibitor, in men. Clinical Pharmacology & Therapeutics. 52(4). 409–412. 5 indexed citations

14.

Conant, Marcus A., et al.. (1989). Disseminated ecthymatous herpes varicella-zoster virus infection in patients with acquired immunodeficiency syndrome. Journal of the American Academy of Dermatology. 20(4). 637–642. 51 indexed citations

15.

Roberts, Richard B., Oscar L. Laskin, Jeffrey Laurence, et al.. (1987). Ribavirin pharmacodynamics in high-risk patients for acquired immunodeficiency syndrome. Clinical Pharmacology & Therapeutics. 42(4). 365–373. 28 indexed citations

16.

Laskin, Oscar L., Donna Cederberg, John Mills, et al.. (1987). Ganciclovir for the treatment and suppression of serious infections caused by cytomegalovirus. The American Journal of Medicine. 83(2). 201–207. 132 indexed citations

17.

Kalman, Concetta M. & Oscar L. Laskin. (1986). Herpes zoster and zosteriform herpes simplex virus infections in immunocompetent adults. The American Journal of Medicine. 81(5). 775–778. 55 indexed citations

18.

Laskin, Oscar L.. (1983). Clinical Pharmacokinetics of Acyclovir. Clinical Pharmacokinetics. 8(3). 187–201. 103 indexed citations

19.

Laskin, Oscar L., James Longstreth, Andrew Whelton, et al.. (1982). Effect of renal failure on the pharmacokinetics of acyclovir. The American Journal of Medicine. 73(1). 197–201. 55 indexed citations

20.

Miranda, P de, Steven S. Good, Oscar L. Laskin, et al.. (1981). Disposition of intravenous radioactive acyclovir. Clinical Pharmacology & Therapeutics. 30(5). 662–672. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact